B. Riley raised the firm’s price target on Eton Pharmaceuticals (ETON) to $31 from $26 and keeps a Buy rating on the shares. Following a strong Q4, Eton delivered enhanced revenue visibility with FY26 guidance above $110M and more than 30% adjusted EBITDA margin, alongside long-term targets of a $200M run-rate exiting 4Q27, 50% margins by 2028, and $500M revenue by 2030, reinforcing a multi-year growth trajectory, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON:
- Eton Pharmaceuticals reports Q4 EPS 5c vs. (2c) last year
- Eton Pharmaceuticals sees FY26 revenue at least $110M, consensus $105.25M
- Is ETON a Buy, Before Earnings?
- Eton Pharmaceuticals participates in a conference call with Craig-Hallum
- Eton Pharmaceuticals price target raised to $30 from $29 at Craig-Hallum